CORE-008 ? BIOMEDICAL INFORMATICS SHARED RESOURCE (BISR) PROJECT SUMMARY / ABSTRACT The OSUCCC Biomedical Informatics Shared Resource (BISR) provides a comprehensive suite of services, technologies and expertise that collectively support the resource-efficient conduct of basic, clinical/translational and population science for OSUCCC investigators.
The Specific Aims of the BISR are: 1) to provide state-of- the-art bioinformatics and computational biology services for the analysis of massively parallel sequence data and the analysis of microarray datasets; 2) to provide OSUCCC investigators with services, expertise and access to technology platforms in support of heterogeneous and multi-dimensional biomedical data management requirements., The BISR, directed by Drs. Jeff Parvin (Aim 1) and Philip Payne (Aim 2), is supported through a combination of CCSG and project-specific grant funds (via charge-back mechanisms), as well as significant and ongoing institutional commitments of human, computational, and financial resources. During the prior five year grant period, the BISR was used by 45 OSUCCC members (59% of total users), but they accounted for 95.7% of usage. The BISR contributed to 195 publications, 29 with a journal impact factor greater than 10 and supported 21 NCI grants through billable services (charegebacks) (1 K12, 1 K24, 4 P01s, 2 P50s, 7 R01s, 1 R21, 1 R37, 1 RC2, 1 U01, 1 U10, and 1 U54). This is in addition to 18 BISR (Aim 1) staff members who have had directly funded appointments on NCI grants (i.e., 3 P01s, 2 P50s, 8 R01s, 1 R21, 1 RC2, 4 U01s, and 1 U54), other grants, and/or OSUCCC institutional funding sources. Through this work, BISR supported investigators from all five of the OSUCCC research programs. The BISR works closely and coordinates services with other OSUCCC shared resources, namely the Behavioral Measurement Shared Resource, the Genomics Shared Resource, the Biostatistics Shared Resource and the Biospecimen Services Shared Resource with its Total Care Cancer protocol. The future plans of the BISR are to streamline and strengthen existing next generation sequencing (NGS) data analysis pipelines through integration of new commercial programs, establish novel data visualization and visual analytics platforms, enhance the OSUCCC researchers abilities to access clinical data through an OSUCCC Information Warehouse serving as the honest broker and employing innovative electronic data capture tools, and fully implementing the Total Cancer Care protocol integration with other cancer centers for real time access to larger sets of electronic health records linked to biospecimens. The BISR leverages extensive institutional support and seeks only 7.0% support from CCSG funds. The Biomedical Informatics Shared Resource is part of the Analytics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-42
Application #
9390846
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Ghoussaini, Maya; Edwards, Stacey L; Michailidou, Kyriaki et al. (2018) Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 9:16193

Showing the most recent 10 out of 2602 publications